Matthias Jeschke

Essen, NW 45147, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Muscle and fat matter: Automated CT-based body composition analysis predicts survival in Hepatocellular carcinoma patients undergoing radioembolization.

Muscle and fat matter: Automated CT-based body composition analysis predicts survival in Hepatocellular carcinoma patients undergoing radioembolization.

Journal: European journal of radiology open
Published: September 24, 2025

No More Detours: Hepatopulmonary Shunt Reduction in a Patient with Hepatocellular Carcinoma after Treatment with Bevacizumab.

No More Detours: Hepatopulmonary Shunt Reduction in a Patient with Hepatocellular Carcinoma after Treatment with Bevacizumab.

Journal: Liver cancer
Published: April 14, 2025

Evaluation of Inflammatory Markers as Prognostic Factors in the Treatment of Hepatocellular Carcinoma (HCC) with Degradable Starch Microspheres by Transarterial Chemoembolization (DSM-TACE).

Evaluation of Inflammatory Markers as Prognostic Factors in the Treatment of Hepatocellular Carcinoma (HCC) with Degradable Starch Microspheres by Transarterial Chemoembolization (DSM-TACE).

Journal: Cancers
Published: December 21, 2024

Systemic Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Multicenter Trial.

Systemic Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Multicenter Trial.

Journal: Cancers
Published: May 24, 2024

Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab.

Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab.

Journal: Cancers
Published: July 24, 2023

Voxel-Based Dosimetry Predicts Hepatotoxicity in Hepatocellular Carcinoma Patients Undergoing Radioembolization with 90Y Glass Microspheres.

Voxel-Based Dosimetry Predicts Hepatotoxicity in Hepatocellular Carcinoma Patients Undergoing Radioembolization with 90Y Glass Microspheres.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 05, 2022

Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis.

Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis.

Journal: Cancers
Published: March 22, 2022

Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience.

Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience.

Journal: Therapeutic advances in medical oncology
Published: October 04, 2021
Showing 1-8 of 8

Last Updated: 09/26/2026